Patient Access to Treatment

Sanofi Genzyme believes that developing life-saving therapies carries with it the responsibility to increase access to these treatments for patients, regardless of their location, financial situation, or other circumstances.
Our Top Priority

All the work that goes into creating an effective therapeutic product means nothing if that treatment can't reach the patients who need it. But whether for financial, geographic, or logistical reasons, access to treatment remains an ongoing challenge for many patients around the world. That's why at Sanofi Genzyme, our commitment to patients – and our efforts to ensure their access to our therapies – extends far beyond the lab and manufacturing plant.

Compassionate Use

We understand that many patients and their families may have particular interest in accessing Sanofi Genzyme’s therapies prior to their approval. While safety is our priority, we may provide eligible patients, without any available treatment options, access to an unapproved investigational treatment through our compassionate use program. 

For more information, please visit Sanofi’s Compassionate Use Policy.

Sanofi Genzyme works with local governments around the world to secure timely approval of our products. While approvals are pending, we've helped patients with urgent medical needs obtain access to our therapies through compassionate use or expanded access programs. We work with national health services and private insurers to establish coverage for our products. And where coverage is not available, we work to facilitate free treatment access, help patients find alternative funding, and help countries establish sustainable health care systems. We also provide a range of educational and support services to raise disease awareness and advocate on behalf of patients' needs.

Health Care Reform in the United States

At Sanofi Genzyme, we are committed to helping patients access our therapies. While the impact of the U.S. health care legislation is not yet known, we continue to closely monitor the health care environment to understand how it may affect patients with rare diseases.

We understand you may have concerns and we are committed to maintaining a high level of service through our patient support programs that include:

  • Helping patients navigate the complexities of their insurance plans (both private and public)
  • Researching alternative forms of funding and reimbursement
  • Access to educational resources and programs for patients to learn more about their disease and treatment
  • Assigning individual case managers who work one-on-one with patients in the U.S. to help obtain ongoing access to treatment
  • Providing charitable or subsidized treatment for eligible patients with no other options

For more than 25 years, Sanofi Genzyme has been committed to supporting patients and addressing barriers to treatment. Our dedicated case managers have helped patients navigate many challenges and will continue to provide support through any upcoming changes.

Last Updated: 8/16/2017
Contact Us
Genzyme Corporation

500 Kendall Street
Cambridge, MA 02142
T: 617-252-7500
F: 617-252-7600

Send Email
Support Services
Reaching Out to Patients

Learn about the programs and services Sanofi Genzyme provides to help patients obtain access to our treatments.

> <